DTx Pharma announces acquisition by Novartis - PR Newswire
WEBSAN DIEGO, July 17, 2023 /PRNewswire/ -- DTx Pharma, a preclinical stage biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its Fatty Acid Ligand...
Novartis builds on neuroscience pipeline and xRNA platform …
WEBBasel, July 17, 2023 — Novartis announced today that it has acquired DTx Pharma, a San-Diego based, preclinical stage biotechnology company focused on leveraging its proprietary FALCON platform to develop siRNA therapies for neuroscience indications.
Here’s Why Novartis Is Paying $500M to Acquire a ... - MedCity News
WEBJul 18, 2023 · Novartis’s acquisition of DTx Pharma brings a lead program for a rare disease with no FDA-approved therapies. But the deal could also help the pharma giant bring new RNA therapies to new places...
Novartis snaps up rare disease biotech DTx Pharma in $1bn deal
WEBJul 18, 2023 · Novartis snaps up rare disease biotech DTx Pharma in $1bn deal. The acquisition adds an siRNA delivery platform to Novartis’s armament and a potential first-in-class treatment for Charcot-Marie-Tooth Disease.
Novartis buys a preclinical biotech and its RNA drug technology
WEBJul 17, 2023 · Swiss drugmaker Novartis said Monday it has acquired biotechnology company DTx Pharma and its pipeline of neurological disease drugs. Per deal terms, Novartis will pay $500 million upfront and could owe up to $500 million more if certain milestones are met.
Novartis Acquires DTx Pharma in Deal Worth Up to $1 Billion
WEBJul 20, 2023 · Under the acquisition, Novartis will gain access to the FALCON platform as well as DTx Pharma’s lead program, DTx-1252, a product candidate that targets the root cause of a subtype of Charcot-Marie Tooth disease (CMT)—CMT1A.
DTx Pharma announces acquisition by Novartis | Markets Insider
WEBSAN DIEGO, July 17, 2023 /PRNewswire/ -- DTx Pharma, a preclinical stage biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its Fatty Acid Ligand...
Novartis Bolsters Neuro Pipeline, RNA Capabilities with Up-to-$1B DTx …
WEBJul 17, 2023 · Novartis has acquired DTx Pharma for up to $1 billion, the companies said, in a deal designed to strengthen the buyer’s neuroscience pipeline and expand its capabilities in RNA therapeutics.
DTx Pharma is Acquired by Novartis - American Pharmaceutical …
WEBJul 17, 2023 · DTx Pharma, a preclinical stage biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its Fatty Acid Ligand Conjugated OligoNucleotide (FALCON™) platform, announced today that it …
DTx Pharma Completes $100M Series B Financing to Advance its ... - BioSpace
WEBMar 1, 2021 · DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today the completion of a $100 million Series B financing.
Skip to content